Revvity stock climbs after earnings beat and $14.09 billion market cap
Published on 08/28/2026 at 10:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revvity Inc. (US76155R1086) has a $14.09 billion market value after the company reported $1.41 in adjusted EPS on August 4, 2026, beating the $1.21 consensus by $0.20. Revenue came in at $729.69 million, above the $702.96 million estimate, while the quarterly top line was down 1.3% from a year earlier.
Earnings still set the tone
The latest quarter remains the clearest reference point for Revvity stock. In the same report, the company said FY 2026 guidance stands at $5.30 to $5.40 in EPS, and analysts were clustered around $5.36 for the full year.
That gap is small, but it matters for valuation because the shares were quoted at $126.31, with a P/E ratio of 60.15 and a beta of 1.07 in the latest market snapshot.
Consensus stayed firm
New analyst commentary from the latest estimate update put Q4 2026 EPS at $1.64, down from $1.67, while keeping the full-year 2026 view at $5.36. That leaves the market focused on whether Revvity can hold the beat-and-raise pattern into the next report.
Historically, the same source set also showed last year’s quarterly EPS at $1.18, which makes the move to $1.41 in the current quarter a $0.23 year-over-year improvement.
Diagnostic demand matters
Revvity's product mix still leans on diagnostics and life-science instrumentation, where recurring consumables and installed-base demand help offset quarter-to-quarter swings. The recent quarter's $729.69 million revenue print and 8.16% net margin show why investors keep watching execution more than the headline revenue dip.
For a representative product line, Revvity's work in newborn screening and immunoassay systems remains central to its platform and supports the current earnings framework.
Shares and valuation
As of August 27, 2026, the stock was quoted at $126.31, while the company carried a $14.09 billion market cap and a 52-week range that placed the shares well above the low end of the band. The next earnings date was not included in the available inputs.
More on Revvity stock
Company: Revvity Inc.
ISIN: US76155R1086
Ticker: RVTY
Exchange: NYSE
Sector / Industry: Health Care / Life Sciences Tools & Services
Index membership: S&P 500
Market cap: $14.09 billion
Price: $126.31 as of August 27, 2026
Summary: The August 4, 2026 quarter delivered $1.41 EPS on $729.69 million in revenue, both ahead of estimates. FY 2026 guidance at $5.30 to $5.40 EPS still frames the stock. Valuation remains elevated with a $14.09 billion market cap and a P/E of 60.15.
Tags: Revvity stock, health care, earnings
